As mental health disorders continue to rise worldwide, researchers are increasingly turning to psychedelic-assisted therapy as a possible new treatment for conditions such as depression and post-traumatic stress disorder, particularly in patients who do not respond to conventional care.
Scientists and mental health experts say the growing interest reflects frustration with the limited progress in psychiatric medicine over recent decades. According to the World Health Organization, more than one billion people globally are living with mental health conditions, placing pressure on healthcare systems to find more effective therapies.
Psychedelic-assisted treatment typically combines controlled doses of psychoactive substances with professional psychological support in carefully monitored settings. Patients are guided through the experience by trained clinicians, often in quiet rooms designed to reduce stress and encourage emotional openness.
Among the substances under study, psilocybin — the active compound found in so-called magic mushrooms — has emerged as one of the most promising. Researchers say it may help patients break free from rigid patterns of thinking commonly linked to severe depression.
Dr Liliana Galindo, assistant professor in psychiatry at the University of Cambridge, said psychedelic research offers hope for patients who have exhausted existing treatment options.
“Unfortunately, in psychiatry, we haven’t really had many new treatments for decades,” she said. “Psychedelics are opening the possibility for treatments aimed at people who do not respond to standard therapies.”
A synthetic form of psilocybin known as COMP360 has already completed phase three clinical trials for treatment-resistant depression. Developers are expected to seek approval from the US Food and Drug Administration, raising the possibility that psilocybin could become the first approved psychedelic-based mental health treatment.
Researchers believe psychedelics work differently from traditional antidepressants. Rather than only easing symptoms, they may temporarily alter brain activity in ways that allow patients to rethink traumatic memories, emotional responses and long-standing negative thought patterns.
Studies from institutions including Imperial College London suggest even a single controlled dose of psilocybin may produce measurable changes in brain function.
Other compounds, including MDMA, are also being studied for their potential to treat PTSD by helping patients revisit traumatic memories in a less fearful state.
Despite the growing scientific interest, significant obstacles remain. Psychedelics are still illegal in many countries and are often associated with recreational drug use. In the United Kingdom, substances such as psilocybin remain classified as Class A drugs, creating strict licensing requirements for researchers.
Experts also warn that psychedelic treatments should never be used without medical supervision. Controlled environments, trained therapists and careful patient screening are considered essential to reduce risks and manage possible side effects.
Researchers say more studies are still needed to determine who benefits most from psychedelic-assisted therapy. However, supporters believe the field could eventually transform mental healthcare if treatments prove both safe and effective.
